# Another Molecule You Cannot Buy

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/another-molecule-you-cannot-buy

> A dual agonist reported 14.7% weight loss in thirteen weeks. The drug is approved nowhere, and a thirteen-week figure sits on the steepest part of a curve that flattens.

## Key points

- −14.7% at 15 mg over 13 weeks vs −1.7% placebo; 93% lost ≥5%.
- You cannot annualize it, because weight loss in this class is front-loaded.
- The ≥10% proportion is a stated secondary endpoint and is NOT in the published abstract.
- 140 on active, 34 on placebo, 13 weeks, diabetes excluded.
- A phase 2 figure; phase 3 is under way. No approval anywhere, no label, no legal route to a pharmacy.

A phase 2 trial of VK2735, another dual GIP/GLP-1 agonist, reported **14.7% weight loss in thirteen weeks**.[1] That is a faster rate than anything on the market has published, and it is about to be quoted without the second half of the sentence. The drug is not approved anywhere, and a thirteen-week result cannot be stretched into a year, because the curve flattens.

## What the trial reported

VENTURE enrolled adults carrying excess weight who also had at least one condition tied to it, excluded anyone with diabetes, and assigned them weekly injections of VK2735 at one of several strengths or a placebo, for 13 weeks.

*VENTURE at week 13. 140 participants across active doses, 34 on placebo.[1]*

| Group | Weight change | Percent |
| --- | --- | --- |
| VK2735 2.5 mg | −9.2 kg | −9.1% |
| VK2735 15 mg | −14.6 kg | −14.7% |
| Placebo | −1.8 kg | −1.7% |

Across the active arms, 130 of 140 people (93%) shed 5% or more. On placebo, 4 of 34 did. Adverse events were gastrointestinal, as expected, and became less frequent once the dose stopped climbing.

## Why you cannot annualize this

> **Weight loss on these drugs is front-loaded.** The curve is steepest in the first months and flattens as it goes. Every long trial in this class shows the same shape. Multiplying a 13-week figure by four produces a number no trial has ever recorded in any drug. If you take 14.7% and project a year, you get 59%, which is not a real quantity.

The fair comparison is with where the established drugs stood at *their* thirteenth week, not with a 68- or 72-week result, and those earlier figures are not reported alongside this one. A short trial can look extraordinary purely by being measured during the steep part of the curve.

The trial itself is a dose-ranging phase 2 doing what a dose-ranging phase 2 should. The caution is about the sentence that will circulate.

## The endpoint the abstract does not report

The trial’s stated secondary endpoints include the proportion of participants losing at least 5% *and* the proportion losing at least 10%. The published abstract reports the first (93% against 12%) but not the second.

The 10% threshold is the more informative of the two, because 5% is cleared by most people on any drug in this class and does not discriminate between them. We do not know what that figure was, we are not going to estimate it, and its absence from a summary that reports its companion deserves a reader’s attention.

> For context on who is reporting: the paper carries a copyright line reading © 2026 Viking Therapeutics, Inc., the company developing the drug. That is a normal arrangement for industry-sponsored publication and it is a fact a reader should have.

## And it is not something you can be prescribed

VK2735 has moved on to phase 3. Two 78-week trials, VANQUISH 1 in about 4,500 people without diabetes and VANQUISH 2 in about 1,100 with it, started in June 2025 and have finished enrolling; ClinicalTrials.gov estimates primary completion in July 2027.[2][3] Until those report, the drug has no approval in any country, no label, no approved manufacturer, and no route to a pharmacy. In practice that means the same thing it meant for retatrutide: a promising early result raises demand that the legitimate supply chain cannot meet, and unlabeled vials appear online to fill the gap.

> Until VANQUISH 1 and 2 report, VK2735 has no approval in any country, no label and no route to a pharmacy.

The material used in this trial was manufactured to clinical-trial standard, at a verified concentration, with a known impurity profile. A powder sold under the same name has none of those properties verified, because there is no approved product to verify it against. The same reasoning, at greater length, is in [retatrutide’s phase 3 and the gray market](https://glpwatchdog.org/research/retatrutide-phase-3-and-the-gray-market).

## Frequently asked questions

### How much weight did VK2735 produce?

In a 13-week phase 2 trial, 14.7% at the 15 mg dose and 9.1% at 2.5 mg, against 1.7% on placebo. Across the active arms, 93% shed 5% or more of their starting weight.

### Is that better than semaglutide or tirzepatide?

The trial does not answer that. It ran for 13 weeks, and weight loss in this class is front-loaded: the curve is steepest early and flattens. Comparing a 13-week result to a 68- or 72-week one measures the length of the trial as much as the drug.

### Can I project the rate forward?

No. Multiplying 14.7% over 13 weeks by four gives 59%, a figure no trial of any drug in this class has recorded. The curve does not continue at its early slope.

### Is VK2735 available?

No. It is in phase 3 trials that are not expected to finish before mid-2027, and it has no approval in any country, no label and no legal route to a pharmacy. Anything sold under that name online has no verified identity, purity or concentration.

### How many people lost 10% or more?

The published abstract does not report it, although the proportion losing at least 10% is listed among the trial's secondary endpoints. Only the 5% threshold is given.

## References

1. Bays HE, Toth P, Alkhouri N, et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity. 2026. PMID: 41508550. https://pubmed.ncbi.nlm.nih.gov/41508550/
2. U.S. National Library of Medicine VK2735 for Weight Management Phase 3 (VANQUISH 1), NCT07104500. ClinicalTrials.gov, accessed October 17, 2026. 2026. https://clinicaltrials.gov/study/NCT07104500
3. U.S. National Library of Medicine VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2), NCT07104383. ClinicalTrials.gov, accessed October 17, 2026. 2026. https://clinicaltrials.gov/study/NCT07104383

---

Cite as: GLP Watchdog, Nora Bissett, "Another Molecule You Cannot Buy", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/another-molecule-you-cannot-buy

Canonical HTML page: https://glpwatchdog.org/research/another-molecule-you-cannot-buy

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
